Popular pharmaceutical company, Merck & Co, is looking forward to introduce oral investigational cancer drug, ridaforolimus, to its European and US regulators later this year.

Merck & Co's experimental blood lump stopper vorapaxar can be a root cause of bleeding in patients who before experienced a knock, investigators concerned in clinical tests of the drug established it on Wednesday.

As a major shock to the pharmaceutical company, Merck & Co lost the second trial over its drug, Fosamax. As per the claims, the drug causes jaw death.

Post the loss, Merck may have to pay $8 million as damage charges.

The case was filed against the company by Shirley Boles, 72 and who was awarded $ 3 million by the court as against her demand of $5 million.

Merck & Co. said on Friday that its proceeds will be impacted unconstructively by about $170 million throughout the existing financial year as a result of health-care legislation, and the company anticipated a negative impact of up to $350 million in the subsequent year.

The new anti-clotting drug produced by Merck & Co. and Portola Pharmaceuticals Inc., called betrixaban, has shown greater effectiveness than warfarin. A recent study has observed that the patients of atrial fibrillations suffered lesser bleeding when given a light dose of betrixaban than those who were given warfarin. Warfarin is essentially a 50 year old blood thinner.

Merck's local unit MSD Australia has been held liable in Australian Vioxx case. Slater & Gordon Ltd. had filed a case against the global pharmaceutical giant Merck & Co Inc., claiming that the Vioxx drug have doubled the risk of heart attacks. Graeme Peterson, 59, also stated that he suffered a heart attack after taking the drug and after that he was unable to work.

After the completion of company purchase of rival Schering-Plough Corp., the second largest U. S. drug maker Merck & Co. claimed its fourth-quarter profit mounted for revenue to beat analyst estimates by 1 cent.

For its newly-created post of Chief Medical Officer, drug-maker Merck & Co has appointed the 62-year-old Harvard-trained endocrinologist, Dr. Michael Rosenblatt, who has been serving as the dean of Tufts University School of Medicine since 2003.

A new study suggests that administering boys with cervical cancer vaccine shots Gardasil to prevent the virus from passing to girls through sex may not be worth the price of doing so on a widespread basis.

Shareholders of both, Merck & Co and Schering-Plough have backed the merger of the two U. S. drug-makers in their special meeting on Friday.

The merging of the two companies would make Merck & Co to become world's no. 2 drug-maker in terms of prescription medicine sales, just behind Pfizer Inc.